Skip to main content

Table 1 Response to personalized treatment (including olaparib): MINT analysisTumor showed significant regression under personalized treatment approach using olaparib, carboplatin and paclitaxel (data shown before and 3 months after initialization of personalized treatment)

From: Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel